目的 探究肺力咳合剂联合沙美特罗替卡松粉吸入剂治疗儿童支气管哮喘的临床疗效。方法 选取2016年12月—2018年12月天津市儿童医院收治的142例支气管哮喘患儿为研究对象，将所有患儿随机分为对照组和治疗组，每组各71例。对照组患儿吸入沙美特罗替卡松粉吸入剂，1吸/次，1次/d；治疗组在对照组治疗的基础上口服肺力咳合剂，10 mL/次，3次/d。两组患儿持续治疗3个月。观察两组的临床疗效，比较两组的临床症状缓解时间、肺功能指标、血气指标、血清炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为84.51%、95.77%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组患儿喘憋、咳嗽、肺部啰音消失时间显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患儿第一秒用力呼气容积（FEV1）、用力肺活量（FVC）和FEV1/FVC均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患儿肺功能指标明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患儿全血氧分压（pO₂）水平明显升高，二氧化碳分压（pCO₂）水平明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患儿血气指标水平显著优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患儿肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平均显著降低，干扰素-γ（IFN-γ）水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患儿血清炎性因子水平明显优于对照组，两组比较差异有统计学意义（P<0.05）。结论 肺力咳合剂联合沙美特罗替卡松粉吸入剂治疗儿童支气管哮喘具有较好的临床疗效，可缩短临床症状缓解时间，改善肺部功能，降低血清炎性因子水平，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Feilike Mixture combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation in treatment of bronchial asthma in children. Methods Children (142 cases) with bronchial asthma in Tianjin Children's Hospital from December 2016 to December 2018 were randomly divided into control and treatment groups, and each group had 71 cases. Children in the control group were inhalation administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 inhalation/time, once daily. Children in the treatment group were po administered with Feilike Mixture on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and clinical symptom remission time, pulmonary function indexes, blood gas indexes, and the serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.51% and 95.77%, respectively, and there was difference between two groups (P<0.05). After treatment, the disappearing time of wheezing, cough and lung rales in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment, FEV1, FVC, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of pO₂ in two groups were significantly increased, but the levels of pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood gas indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TNF-α and IL-6 in two groups were significantly decreased, but the levels of IFN-γ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the serum levels of inflammatory factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Feilike Mixture combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation has clinical curative effect in treatment of bronchial asthma in children, can shorten remission time of clinical symptoms, improve pulmonary function, and reduce the level of serum inflammatory factors, which has a certain clinical application value.